Free Trial

Piper Sandler's Rating of BridgeBio Pharma on 8/11/2026

On August 11, 2026, Piper Sandler updated its outlook on BridgeBio Pharma (NASDAQ:BBIO) with the action "Boost Price Target", setting a price target of $115.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Piper Sandler

DateCompanyAction
10/15/2026
The Cooper Companies, Inc. stock logo
COO
Cooper Companies
Reiterated Rating
10/15/2026
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
Reiterated Rating
10/15/2026
Redwire Corporation stock logo
RDW
Redwire
Initiated Coverage
10/15/2026
HAWK
HawkEye 360
Initiated Coverage
10/15/2026
York Space Systems Inc. stock logo
YSS
York Space Systems
Initiated Coverage
10/15/2026
National Bank Holdings Corporation stock logo
NBHC
National Bank
Lower Price Target
More Ratings From Piper Sandler